Shire earnings jump but sales disappoint

Drug maker Shire lifted first-quarter earnings 10 per cent but revenues missed consensus estimates by 5.0 per cent.

Drug maker Shire lifted first-quarter earnings 10 per cent but revenues missed consensus estimates by 5.0 per cent.

Product sales in the three months to end-March 2013 were up 1.0% to $1.1bn against a strong set of comparatives from the equivalent period in 2012, but this was less than analysts were expecting.

Sales of Replagal for sufferers of Fabry disease fell 15% due to issues with shipments and competition, while the restructuring of the sales and marketing model for Dermagraft foot ulcer treatment saw its sales fall 62%.

Compensating for these falls, Dublin-headquartered Shire enjoyed particularly strong performances from Vyvanse for children with attention-deficit disorder (ADHD), hyperactivity treatment Intuniv and Lialda for colitis, leading to group earnings advancing 10% to $1.63 per share on a non-GAAP basis and generating $257m of cash during the quarter.

As he set out his strategy for Shire's future, new Chief Executive Officer Flemming Ornskov said: "Shire has consistently delivered growth significantly above the industry levels of mid single digit and we intend that this will be the case in the future."

Ornskov's growth strategy is to sharpen the group's focus on "commercial excellence" of currently marketed products and "pipeline innovation" through research and development and business development.

Broker Jefferies notes that management are confident in meeting earnings forecasts of $6.67 earnings per ADS, but are now targeting lower sales growth due to weaker Replagal and Dermagraft.

The broker said: "As a growth story we believe lower top-line momentum [will] drive stock weakness, but longer-term valuation and pipeline drive our 'buy'."

Shares in Shire were down 6.4% at 1,890p at 15:20 on the day of the announcement.

OH

Recommended

Why it pays to face up to your investment mistakes
Investment strategy

Why it pays to face up to your investment mistakes

Buying stocks can be a complicated business. But selling stocks can be tricky, too – even if you sell for the right reasons. Max King explains how to …
17 Sep 2021
Share tips of the week – 17 September
Share tips

Share tips of the week – 17 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Sep 2021
Royal Mail will deliver for investors – here's how to play it
Trading

Royal Mail will deliver for investors – here's how to play it

Royal Mail Group has found its feet in the past 18 months and looks cheap. Matthew Partridge looks at how to trade the shares.
14 Sep 2021
The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021

Most Popular

The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021